title: Current antiplatelet agents: place in therapy and role of genetic testing.
abstract: Antiplatelet therapies play a central role in reducing the risk of cardiovascular events such as myocardial infarction and stroke. While aspirin, a cyclo-oxygenase-1 inhibitor has been the cornerstone of antithrombotic treatment for several decades, P2Y12 receptor inhibitors cangrelor, clopidogrel, prasugrel, and ticagrelor and protease-activated receptor-1 antagonist vorapaxar, have emerged as additional therapies to reduce the risk of recurrent cardiovascular events in high-risk patients. Recent clinical trials evaluating the role of these agents and major society guideline updates for use of antiplatelet therapies for secondary prevention of cardiovascular events will be examined. The latest studies regarding the appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention will be presented. The current state of genetic and platelet function testing will be reviewed.
authors.affiliation: Division of Cardiology, University of Washington Medical Center, 1959 NE Pacific Street, Box 365005, Seattle, WA, 98195, USA, eyang01@uw.edu.
authors.forename: Eugene
authors.initials: E
authors.lastname: Yang
mesh_terms: D005820:Genetic Testing; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy / Q000235:genetics; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D058925:Receptors, Purinergic P2Y12 / Q000235:genetics / Q000378:metabolism; D020521:Stroke / Q000188:drug therapy / Q000235:genetics
chemical_list: D007783:Lactones; C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D011725:Pyridines; D058925:Receptors, Purinergic P2Y12; C530299:vorapaxar